Clinical Trial Update: Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating whether entecavir can reduce hepatitis in highly viremic hepatitis B patients undergoing anti-tuberculous treatment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B
• Tuberculosis

Drugs mentioned

• Baraclude (entecavir)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Hepatitis, Tuberculosis | Phase 4 | Status: UNKNOWN